These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34334529)

  • 1. Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.
    Terakami T; Nagaya S; Hayashi K; Furusho H; Fujino N; Kato T; Asakura H; Morishita E
    J Atheroscler Thromb; 2022 Jul; 29(7):1059-1068. PubMed ID: 34334529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
    Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
    Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
    Platton S; Hunt C
    Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
    Vercruyssen J; Meeus P; Bailleul E
    Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
    Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
    J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents.
    Kumano O; Suzuki S; Yamazaki M; An Y; Yasaka M; Ieko M;
    Int J Lab Hematol; 2023 Feb; 45(1):119-125. PubMed ID: 36114152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assay to measure levels of factor Xa inhibitors in blood and plasma.
    Kim PY; Di Giuseppantonio LR; Wu C; Douketis JD; Gross PL
    J Thromb Haemost; 2019 Jul; 17(7):1153-1159. PubMed ID: 30985986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
    Ząbczyk M; Natorska J; Kopytek M; Malinowski KP; Undas A
    Arch Pathol Lab Med; 2021 Jan; 145(1):99-104. PubMed ID: 33367661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.